A Stalking Horse Bid from a ~$24 Billion BioPharma Behemoth Could Breathe Life into this unknown 8 cent stock
Ico Therapeutics, Inc. (OTC QB: ICOTF)(TSX: ICO.V) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat infectious and ocular diseases.
Their Vision is to make “existing drugs more effective and easier to deliver.”
ICOTF is focused on two main drug candidates, iCo-008, named Bertilimumab, or “Bert” for short, and ICO-019 named Amphotericin B, or “Oral Amp B” for short.
ICOTF has licensed the exclusive world-wide rights to Bertilmumab/iCo-008. The asset was originally developed by Cambridge Antibody, and acquired by AstraZeneca upon its purchase of Cambridge. In 2007, ICO licensed it. Then in 2010, ICO licensed the systemic rights to Immune Pharmaceuticals, while ICO maintained all ocular rights. As part of the deal, ICO was entitled to $32 million in milestone payments and 8.5% royalty on iCo-008 sales.
Now the story takes a fascinating turn. Immune Pharmaceuticals filed for bankruptcy and the assets were put up for court auction. Court filings show that Alexion Pharmaceuticals, a $24 Billion behemoth, placed a stalking horse bid for $6M and won the systemic rights.
Why would Alexion bid for Bert? The asset has shown “clinical efficacy in a highly deleterious condition” meaning – it works. It has passed Phase II of the FDA approval process and awarded an orphan drug designation by both the FDA and the EMA -European Medicines Agency.
The FDA has granted Fast Track Designation to Bert for the treatment of a dermatological condition called Bullous Pemphigoid (BP). BP is an autoimmune disorder which causes painful and itchy fluid-filled blisters, primarily in elderly patients. The global outlook for BP is projected to grow considerably over the next few years.
Bert is also a candidate for treating Ulcerative Colitis and has completed recruitment for a new clinical study.
Alexion is widely regarded as the largest pure-play orphan drug disease company with greater than $4Billion in annual sales. In fact, every one of Alexion’s marketed products have Orphan Drug designations. Orphan drugs have potential to be big sellers. Alexion’s top selling drug Soliris, which has orphan designation for three indications, produced over $3.5 Billion of revenue in 2018.
The stalking horse bid sets a minimum value for the asset. ICO will not receive any proceeds from this sale, but they benefit from the greater likelihood of receiving its development milestone payments ($32.0 Million), and royalty revenues (8.5%), if/when the product is commercialized.
Regulatory filings for both ICO and Immune indicate that the first of the $32 million in milestone payments to ICO occur once the first patient is dosed in a Phase 3 study with iCo-008. If Alexion ends up being the new partner, they have the ability and means to push for a phase 3. The payments would be triggered and ICO would stand to receive upfront cash and milestone payments.
ICOTF could end up with Alexion as a huge partner for this asset. ICO still owns the Ocular rights, and Alexion may want to enter into a new licensing agreement. Or they may want to buy them outright! It’s not out of the question to think Alexion would want 100% ownership of the intellectual property to control any future product commercialization. According to court filings Immune and Alexion were in discussions prior to Immune filing for Chapter 11, so the interest has always been there.
ICOTF has solicited bids from CRO’s for assistance with this Ocular asset, and is engaging with the FDA to run an additional Phase 2 study in Ophthalmology.
There are so many ways this could play out, and ICO seemingly stands to benefit from all.
ICOTF has taken a decades old IntraVenous (I.V.) generic drug and converted it to a proprietary oral drug.
Amphoericin B Delivery System is a generic drug which is currently administered intravenously to treat fungal infections and Visceral Leishmaniasis, an often fatal disease caused by a parasite. Amphotericin B (Amp B) has been a gold standard for highly efficacious treatment of systemic fungal and parasitic infections with more than a 50-year history of intravenous (IV) formulations. In fact, it produced $366M in sales in 2017 for Gilead.
An oral version of the drug has yet to be developed.
ICOTF has developed an oral Amp B formulation which may have significant advantages over an IV formulation with fewer adverse events and an easier way of administration. Oral formulations could resolve safety and delivery issues which would enable broader patient access.
Oral delivery of the drug would be of paramount interest to pharmaceutical and insurance companies. The cost to administer IV drug treatments is substantial and poses risk of infections or complications.
An estimated 1.5 million people globally die from fungal infections. The global antifungal market could be worth as much as $12.7 Billion by 2025.
ICOTF has completed Phase I safety work with their oral Amp B formulation and is preparing to enter a Phase 1b/2a proof-of-concept study. Data from this Phase 2a study should be available in early /mid 2020. They submitted a plan and further additional materials to an Australian IRB (Institutional Review Board) outlining a proposed multi-center study of up to 90 individuals comparing Oral Amp B to current standard of care.
The company recently raised just over $2 Million in a private placement, and raised $1.25M Canadian earlier in the year. They act with “fiscal prudence,” prioritizing scientific and technological advances through leveraging activities, receiving tax credits from the Australian government.
The Bottom Line
Ico Therapeutics, Inc. (OTC QB: ICOTF) was recently given a $0.60 price target by KRC Insights. If this hit, it would represent a 650% return from the current $0.08 price (10/21/2019).
Ico Therapeutics, Inc. (OTC QB: ICOTF) is an under-the-radar company offering a potential upside opportunity for timely investors. Currently trading at a miniscule market cap of under $10.0 Million, this could prove to be highly undervalued compared to all of the short term catalysts listed, which lend credibility to this highly compelling story.
For a better understanding of ICOTF and its business, plus risks of owning its shares, click here to view ICOTF’s SEC filings.
Please read them thoroughly before making any investment decisions.
Thank you for Reading.
DISCLAIMER PLEASE NOTE:
This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ICOTF (and / or any other mentioned companies and / or securities), and read this TRADDR Blogs/profiles are not a solicitation or recommendation to buy, sell or hold securities. TRADDR and/or affiliates may post paid advertisements and is not offering securities for sale. Neither TRADDR nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by TRADDR its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.
TRADDR does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.
Information presented by TRADDR may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.
THIS SITE IS PROVIDED BY TRADDR ON AN “AS IS” AND “AS AVAILABLE” BASIS. TRADDR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.
TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, TRADDR DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. TRADDR DOES NOT WARRANT THAT THIS SITE, OR ITS SERVERS ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. TRADDR MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.
The website contains links to other related World Wide Web Internet sites and resources. TRADDR is not responsible for the availability of these outside resources, or their contents, nor does TRADDR endorse nor is TRADDR responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall TRADDR be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.
TRADDR is owned and operated by New Edge Media, Inc., which is a US based corporation. We often post paid advertisements, also known as stock touts or stock promotions, where TRADDR disseminates favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, TRADDR.com which may get disseminated through social media, Chat rooms, message boards, and the like, which may feature “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be seen by or sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We expect to be paid five thousand dollars by Bello Capital to advertise the Profiled Issuer, ICO Therapeutics. TRADDR has been hired by a third party for a period for a period beginning on October 21st , 2019 to publicly disseminate information about (ICOTF) We will update any changes to our compensation. We own zero shares of (ICOTF) and will not be buying or selling any shares of ICOTF.
We believe and assume that Third Parties paying us to market the Profiled Issuer intend to sell shares they hold while we suggest investors to research and/or purchase during the Campaign. ICO Therapeutics Inc. is a penny stock that may become illiquid (little to no trading volume), and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.
We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.
There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.
If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.